Endovascular Engineering Raises $80 Million in Series C Funding
Endovascular Engineering, a company specializing in innovative solutions for vascular health, has successfully secured $80 million in its Series C funding round. This significant financial boost, dated April 7, 2026, was led by Gilde Healthcare and Norwest, with participation from 415 Capital, M, L Healthcare Investments, Panakès Partners, S3 Ventures, and Santé Ventures.
Leadership and Vision
The company's leadership includes Mike Rosenthal, who serves as the Chief Operating Officer and Co-Founder. Rosenthal's experience and strategic vision have been pivotal in guiding Endovascular Engineering's growth and development within the vascular health sector.
Strategic Use of Funds
While specific details on the allocation of the new funds were not disclosed, companies at this stage typically channel such investments into product development, expanding market reach, and scaling operations. This funding round is expected to enhance Endovascular Engineering's capabilities and support its mission to advance vascular health solutions.
Investors' Confidence
The involvement of prominent investors such as Gilde Healthcare and Norwest, along with others like 415 Capital and S3 Ventures, underscores the strong confidence in Endovascular Engineering's potential to impact the healthcare industry positively. These investors bring not only financial support but also valuable industry expertise and networks that can aid in the company's growth trajectory.
Endovascular Engineering's latest funding round marks a significant milestone, positioning it well for continued innovation and expansion in the field of vascular health.